UK Parliament watchdog wants sluggish value-based pricing discussion for drugs clarified by March
This article was originally published in SRA
The UK Parliament’s Health Select Committee which monitors England's Department of Health is calling for the department to work out plans for value-based pricing by the end of March1. The lack of progress and clarity on the new arrangements so far, it said, is “unacceptable”.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.